Full Press Release Details
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results
Presentation of MitoGelTM Interim Analysis from OLYMPUS Pivotal Trial in Patients with
Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting
Conference Call to be Held Today at 8:30am ET
Ra anana, Israel, and New York, NY, March 15, 2018 UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company
developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for the fourth quarter and full year ended December 31, 2017 and
provided an overview of the Company s recent developments.
Last year was a pivotal year for UroGen. Coming off a successful initial public
offering, we immediately set our goals on working towards establishing a leadership position in the treatment of urothelial cancers and other urological indications, said Ron Bentsur, Chief Executive Officer of UroGen. Our growing team
is focused on executing on key milestones, particularly completion of the pivotal Phase 3 OLYMPUS trial for MitoGel. We are also advancing our other pipeline programs that could allow us to transform the treatment of urothelial cancers and other
urological pathologies, and demonstrate the potential for the RTGel platform beyond oncology.
Recent Highlights and Upcoming Milestones
Fourth Quarter and Full Year 2017 Financial Results
Members of UroGen s management team will host a live conference call and webcast today at 8:30 am Eastern Time to review the
Company s financial results and provide a general business update.
The live webcast can be accessed by visiting the Investors section of the
Company s website at http://investors.urogen.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 771-4371 (U.S.) or (847) 585-4405 (International) to listen to the live conference call. The conference ID number for the live call will be 46558329. An archive of the webcast
will be available for two weeks on the Company s website.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and per share data)
| December 31, 2017 | December 31, 2016 | |||||||
| Assets | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 36,999 | $ | 21,362 | ||||
| Short-term investments | 36,001 | |||||||
| Restricted deposit | 198 | 95 | ||||||
| Accounts receivable | 83 | |||||||
| Inventory | 316 | 105 | ||||||
| Prepaid expenses and other current assets | 958 | 396 | ||||||
| TOTAL CURRENT ASSETS | 74,472 | 22,041 | ||||||
| NON-CURRENT ASSETS: | ||||||||
| Property and equipment, net | 805 | 741 | ||||||
| Restricted deposit | 29 | 24 | ||||||
| Other non-current assets | 244 | 250 | ||||||
| TOTAL ASSETS | $ | 75,550 | $ | 23,056 | ||||
| Liabilities and Shareholders equity | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable and accrued expenses | $ | 4,435 | $ | 1,880 | ||||
| Employee related accrued expenses | 1,950 | 687 | ||||||
| Deferred revenues | 650 | |||||||
| Proceeds from exercise of warrants for preferred shares | 570 | |||||||
| TOTAL CURRENT LIABILITIES | 7,035 | 3,137 | ||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Warrants for preferred shares | 3,612 | |||||||
| TOTAL LIABILITIES | 7,035 | 6,749 | ||||||
| SHAREHOLDERS EQUITY: | ||||||||
| Ordinary shares, NIS 0.01 par value: 100,000,000 and 17,600,000 shares authorized at December 31, 2017 and 2016, respectively; 13,751,390 and 2,305,743 shares issued and outstanding at December 31, 2017 and 2016, respectively. | 37 | 6 | ||||||
| Series A and A-1 preferred shares, NIS 0.01 par value: 0 and 14,400,000 shares authorized at December 31, 2017 and 2016, respectively; 0 and 5,193,427 shares issued and outstanding at December 31, 2017 and 2016, respectively. | 13 | |||||||
| Additional paid-in capital | 115,692 | 43,502 | ||||||
| Accumulated deficit | (47,214 | ) | (27,214 | ) | ||||
| TOTAL SHAREHOLDERS EQUITY | 68,515 | 16,307 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $ | 75,550 | $ | 23,056 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
| Year ended December 31, | Three months ended December 31, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| REVENUES | $ | 8,158 | $ | 17,530 | $ | 327 | $ | 17,530 | ||||||||
| COST OF REVENUES | 600 | 28 | 287 | 28 | ||||||||||||
| GROSS PROFIT | 7,558 | 17,502 | 40 | 17,502 | ||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and Development Expenses, Net | 18,697 | 10,287 | 6,761 | 2,372 | ||||||||||||
| General and Administrative Expenses | 8,811 | 6,417 | 3,437 | 1,229 | ||||||||||||
| OPERATING (LOSS) INCOME | (19,950 | ) | 798 | (10,158 | ) | 13,901 | ||||||||||
| FINANCE (EXPENSES) INCOME, NET | (31 | ) | (2,739 | ) | 91 | (978 | ) | |||||||||
| (LOSS) INCOME BEFORE INCOME TAXES | (19,981 | ) | (1,941 | ) | (10,067 | ) | 12,923 | |||||||||
| INCOME TAX EXPENSE | (19 | ) | ||||||||||||||
| NET (LOSS) INCOME | $ | (20,000 | ) | $ | (1,941 | ) | $ | (10,067 | ) | $ | 12,923 | |||||
| (LOSS) INCOME PER ORDINARY SHARE | ||||||||||||||||
| BASIC | $ | (2.14 | ) | $ | (1.91 | ) | $ | (0.74 | ) | $ | 5.17 | |||||
| DILUTED | $ | (2.14 | ) | $ | (1.91 | ) | $ | (0.74 | ) | $ | 1.56 | |||||
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING | ||||||||||||||||
| BASIC | 9,716,790 | 2,305,503 | 13,612,814 | 2,381,671 | ||||||||||||
| DILUTED | 9,716,790 | 2,305,503 | 13,612,814 | 8,294,273 |
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical
treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel , a proprietary sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs. UroGen Pharma s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective
treatment option. UroGen Pharma s lead product candidates, MitoGel (mitomycin urothelial gel) and VesiGel (mitomycin intravesical gel), are designed to potentially remove tumors by
non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract
urothelial carcinoma and bladder cancer, respectively. UroGen Pharma is headquartered in Ra anana, Israel with U.S. headquarters in New York.
Forward Looking Statements
This press release contains
forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the timing and results of clinical development and commercial prospects of the product candidates in UroGen
Pharma s pipeline, including MitoGel, VesiGel and BotuGel, the scope and development of UroGen Pharma s product candidate pipeline, results from the OLYMPUS trial, patient enrollment in Allergan s Phase 2 clinical trial of
BotuGel, UroGen Pharma s expectations regarding its ability to fund its operations, and the ability of UroGen Pharma to become a leader in the field of uro-oncology, which statements are subject
to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials and potential complications thereof; the ability to obtain and maintain regulatory approval; the labeling for any approved
product; the scope, progress and expansion of developing and commercializing UroGen Pharma s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof
vis- -vis alternative therapies; and UroGen Pharma s ability to attract or retain key management, members of the board of directors and personnel. In light
of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of the final prospectus for
UroGen Pharma s public offering of securities in the United States filed with the SEC on January 22, 2018 and other filings that UroGen Pharma makes
with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen Pharma s actual results could differ
materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen Pharma as of the date of this release.
Corporate Affairs Officer
Director, Corporate Communications & Investor Relations